Table 1.
Clinical and pathology data of subjects
| Group | Pathology | Number | Ratio |
|---|---|---|---|
| High grade (34) | Serous cystadenocarcinoma | 18 | 53% |
| Mucinous cystadenocarcinoma | 8 | 24% | |
| Clear cell carcinoma | 3 | 9% | |
| Yolk sac tumor | 1 | 3% | |
| Adenoid carcinoma of endometrium | 2 | 6% | |
| Granular cell carcinoma | 1 | 3% | |
| Low grade (10) | Borderline serous cystadenoma | 4 | 40% |
| Borderline mucinous cystadenoma | 3 | 30% | |
| Borderline endometrial carcinoma | 2 | 20% | |
| Benign (19) | Chocolate cyst | 9 | 47% |
| Teratoma | 5 | 26% | |
| Mucinous cystadenoma | 3 | 16% | |
| Spindle cell tumor | 1 | 5% | |
| Tuberculous granuloma | 1 | 5% | |
| Age (median, range) | |||
| 35 (16-53) | Premenopausal | 23 | 35% |
| 62 (46-83) | Postmenopausal | 40 | 63% |
| FIGO stage | |||
| Ovarian cancers | I | 13 | 30% |
| II | 6 | 14% | |
| III | 18 | 41% | |
| IV | 7 | 16% | |